News section
home news forum careers events suppliers solutions markets resources directories advertise contacts search site plan
 
.
Devgen's board of directors appoints Pol Bamelis as chairman

.

Zwijnaarde, Belgium
June 1, 2007

Devgen NV (Euronext: DEVG), a leading European biotech company, today announced the appointment of Pol Bamelis as Chairman of the board.

Dr.Bamelis is a senior figure in the agro and pharma industry. He holds board positions in a wide range of Belgian and foreign companies and he is also a member of the board of the University of Leuven. Dr.Bamelis was chairman of the Agfa group from 2002 until mid 2005 and of Crop Design in Ghent until mid 2006.
Dr. Bamelis retired from Bayer in 2001, after 36 years with the company, including 10 years as a Board member with responsibilities for Agro and Pharma R&D. Dr. Bamelis was one of the main architects of Bayer's biotechnology strategy and was closely involved in the company's biotech collaborations.

Pol Bamelis comments: "I am honoured and keen to contribute my experience and network as chairman to help this promising biotechnology company in the next growth stage."

Dr. Bamelis replaces Pierre Hochuli, who will leave the board after 8 years of board membership of which the last 4 years as chairman.

Pierre Hochuli concluded: "It was very rewarding to chair Devgen's board of directors for several years and work with its innovative management to lead the company from an "early stage" enterprise to a successful public biotech company. I am confident that Devgen, under the leadership of Dr. Bogaert and Devgen's board, will capture significant positions in important agricultural markets. I thank management and the board for their support and constructive collaboration and wish the incoming chairman, Dr. Bamelis and the Devgen community all the best for the future."

Devgen is an innovator in biotechnology focused on discovering, developing and commercializing:
- a novel generation of biotech products to protect a wide spectrum of crops from damage incurred from pests;
innovative hybrid rice germplasm and traits focused on Indian farmer's needs;
- safer and more environmentally friendly agro-chemical products to protect crops from damage inflicted by plant parasitic nematodes;
- novel therapeutic concepts and preclinical drug candidates for treatment of metabolic disease (diabetes, obesity, arrhythmia) and inflammation.

Devgen has partnerships with industry leaders in biotechnology and agro chemistry. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore and Hyderabad (India), with a total work force of about 100 people. For more information on Devgen visit the company's web site: www.devgen.com.

 

 

 

 

The news item on this page is copyright by the organization where it originated - Fair use notice

Other news from this source


Copyright © SeedQuest - All rights reserved